Topoisomerase-1, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients
Topoisomerase-1, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients
复制标题
DOI：
10.1002/ijc.20208
复制
发表时间：
2004-08-20
影响因子：
6.4
通讯作者：
Colucci, G
中科院分区：
文献类型：
--
作者：
Paradiso, A;Xu, JM;Colucci, G
虽然有几项研究报告胸苷酸合成酶（TS）肿瘤表达可以作为晚期结直肠癌患者对5-氟尿嘧啶（5-FU）临床应答的可靠预测标志物，但只有少数研究搜索了伊立替康（CPT-11）临床应答的预测因素。本研究的目的是验证免疫组织化学拓扑异构酶-I（Topo-I）和TS原发肿瘤表达的预测价值，在连续系列的62例接受一线5-FU/CPT-11化疗的晚期结直肠癌患者。TS和Topo-I免疫染色分别在76%和43%的肿瘤中观察到，导致每个肿瘤内的显著相关性（r=0.365，p
While several studies have reported that thymidylate synthase (TS) tumour expression can be a reliable predictive marker of clinical response to 5-Fluorouracil (5-FU) for advanced colorectal cancer patients, only a few studies that searched for predictive factors of irinotecan (CPT-11) clinical response are available. The aim of the present study has been to verify the predictive value of immunohistochemical topoisomerase-I (Topo-I) and TS primary tumour expression in a consecutive series of 62 advanced colorectal cancer patients that received a first line 5-FU/CPT-11 chemotherapy. TS and Topo-I immunostaining was observed in 76% and 43% of tumours, respectively, resulting in a significant relationship within each tumour (r=0.365, p